Priority Setting, Cost-Effectiveness, and the Affordable Care Act
- PMID: 26237985
- DOI: 10.1177/0098858815591511
Priority Setting, Cost-Effectiveness, and the Affordable Care Act
Abstract
The Affordable Care Act (ACA) may be the most important health law statute in American history, yet much of the most prominent legal scholarship examining it has focused on the merits of the court challenges it has faced rather than delving into the details of its priority-setting provisions. In addition to providing an overview of the ACA's provisions concerning priority setting and their developing interpretations, this Article attempts to defend three substantive propositions. First, I argue that the ACA is neither uniformly hostile nor uniformly friendly to efforts to set priorities in ways that promote cost and quality. Second, I argue that the ACA does not take a single, unified approach to priority setting; rather, its guidance varies depending on the aspect of the healthcare system at issue (Patient Centered Outcomes Research Institute, Medicare, essential health benefits) and the factors being excluded from priority setting (age, disability, life expectancy). Third, I argue that cost-effectiveness can be achieved within the ACA's constraints, but that doing so will require adopting new approaches to cost-effectiveness and priority setting. By limiting the use of standard cost-effectiveness analysis, the ACA makes the need for workable rivals to cost-effectiveness analysis a pressing practical concern rather than a mere theoretical worry.
Similar articles
-
A Critical Analysis of Obamacare: Affordable Care or Insurance for Many and Coverage for Few?Pain Physician. 2017 Mar;20(3):111-138. Pain Physician. 2017. PMID: 28339427 Review.
-
What Is Federalism in Healthcare For?Stanford Law Rev. 2018 Jun;70(6):1689-803. Stanford Law Rev. 2018. PMID: 30203949
-
ACA and the Triple Aim: Musings of a Health Care Actuary.Benefits Q. 2015;31(1):39-42. Benefits Q. 2015. PMID: 26540942
-
Patient Protection and Affordable Care Act of 2010: reforming the health care reform for the new decade.Pain Physician. 2011 Jan-Feb;14(1):E35-67. Pain Physician. 2011. PMID: 21267047 Review.
-
The impact of comparative effectiveness research on interventional pain management: evolution from Medicare Modernization Act to Patient Protection and Affordable Care Act and the Patient-Centered Outcomes Research Institute.Pain Physician. 2011 May-Jun;14(3):E249-82. Pain Physician. 2011. PMID: 21587337 Review.
Cited by
-
Alternatives to the quality-adjusted life year: How well do they address common criticisms?Health Serv Res. 2023 Apr;58(2):433-444. doi: 10.1111/1475-6773.14116. Epub 2022 Dec 28. Health Serv Res. 2023. PMID: 36537647 Free PMC article.
-
Challenges of Cost-Effectiveness Analyses of Novel Therapeutics for Inherited Retinal Diseases.Am J Ophthalmol. 2022 Mar;235:90-97. doi: 10.1016/j.ajo.2021.08.009. Epub 2021 Aug 22. Am J Ophthalmol. 2022. PMID: 34433085 Free PMC article. Review.
-
Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.Innov Pharm. 2020 Feb 14;11(1):10.24926/iip.v11i1.2444. doi: 10.24926/iip.v11i1.2444. eCollection 2020. Innov Pharm. 2020. PMID: 34017624 Free PMC article.
-
Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies.Innov Pharm. 2019 Oct 31;10(4):10.24926/iip.v10i4.2337. doi: 10.24926/iip.v10i4.2337. eCollection 2019. Innov Pharm. 2019. PMID: 34007580 Free PMC article.
-
ICER, ISPOR AND QALYs: Tales of Imaginary Worlds.Innov Pharm. 2019 Oct 31;10(4):10.24926/iip.v10i4.2266. doi: 10.24926/iip.v10i4.2266. eCollection 2019. Innov Pharm. 2019. PMID: 34007578 Free PMC article.